The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron invested $119.5 million in Truveta ... than 10 times the scale of other health care databases, such as the UK Biobank, which includes 500,000 participants recruited between 2006 ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Regeneron pledged $119.5m while Illumina is ... interplay between genetics and health in unprecedented detail.” The UK Biobank, which holds genetic and health information from 500,000 ...

Regeneron invested $119.5 million in Truveta’s Series C funding ... Truveta touts the endeavor as being more than 10 times the scale of other health care databases, such as the UK Biobank, which ...